

Edimara S Reis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6433360/publications.pdf>

Version: 2024-02-01

52
papers

4,369
citations

159358

30
h-index

182168

51
g-index

54
all docs

54
docs citations

54
times ranked

5508
citing authors

#	ARTICLE	IF	CITATIONS
1	The role of the anaphylatoxins in health and disease. <i>Molecular Immunology</i> , 2009, 46, 2753-2766.	1.0	582
2	Complement in disease: a defence system turning offensive. <i>Nature Reviews Nephrology</i> , 2016, 12, 383-401.	4.1	427
3	Novel mechanisms and functions of complement. <i>Nature Immunology</i> , 2017, 18, 1288-1298.	7.0	364
4	Complement component C3 – The “Swiss Army Knife” of innate immunity and host defense. <i>Immunological Reviews</i> , 2016, 274, 33-58.	2.8	313
5	The renaissance of complement therapeutics. <i>Nature Reviews Nephrology</i> , 2018, 14, 26-47.	4.1	305
6	New insights into the immune functions of complement. <i>Nature Reviews Immunology</i> , 2019, 19, 503-516.	10.6	281
7	Complement in cancer: untangling an intricate relationship. <i>Nature Reviews Immunology</i> , 2018, 18, 5-18.	10.6	279
8	Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2014, 123, 2094-2101.	0.6	172
9	New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. <i>Immunobiology</i> , 2013, 218, 496-505.	0.8	129
10	C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells. <i>European Journal of Immunology</i> , 2010, 40, 710-721.	1.6	113
11	Local Complement-Targeted Intervention in Periodontitis: Proof-of-Concept Using a C5a Receptor (CD88) Antagonist. <i>Journal of Immunology</i> , 2012, 189, 5442-5448.	0.4	100
12	Complement anaphylatoxin C3a is a potent inducer of embryonic chick retina regeneration. <i>Nature Communications</i> , 2013, 4, 2312.	5.8	80
13	Functional Relevance of the Anaphylatoxin Receptor C3aR for Platelet Function and Arterial Thrombus Formation Marks an Intersection Point Between Innate Immunity and Thrombosis. <i>Circulation</i> , 2018, 138, 1720-1735.	1.6	77
14	Sleep and circadian rhythm regulate circulating complement factors and immunoregulatory properties of C5a. <i>Brain, Behavior, and Immunity</i> , 2011, 25, 1416-1426.	2.0	75
15	Pericytes and immune cells contribute to complement activation in tubulointerstitial fibrosis. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 312, F516-F532.	1.3	64
16	Applying complement therapeutics to rare diseases. <i>Clinical Immunology</i> , 2015, 161, 225-240.	1.4	60
17	Complement-Dependent Mechanisms and Interventions in Periodontal Disease. <i>Frontiers in Immunology</i> , 2019, 10, 406.	2.2	60
18	Therapeutic C3 inhibitor Cp40 abrogates complement activation induced by modern hemodialysis filters. <i>Immunobiology</i> , 2015, 220, 476-482.	0.8	58

#	ARTICLE	IF	CITATIONS
19	The Evolution and Appearance of C3 Duplications in Fish Originate an Exclusive Teleost c3 Gene Form with Anti-Inflammatory Activity. PLoS ONE, 2014, 9, e99673.	1.1	54
20	C5a Receptor-Dependent Cell Activation by Physiological Concentrations of Desarginated C5a: Insights from a Novel Label-Free Cellular Assay. Journal of Immunology, 2012, 189, 4797-4805.	0.4	50
21	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncoimmunology, 2017, 6, e1326442.	2.1	48
22	Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene. Molecular Immunology, 2008, 45, 1693-1702.	1.0	44
23	Targeted complement inhibition as a promising strategy for preventing inflammatory complications in hemodialysis. Immunobiology, 2012, 217, 1097-1105.	0.8	39
24	High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity. Molecular Cancer Research, 2016, 14, 953-965.	1.5	38
25	Safety profile after prolonged C3 inhibition. Clinical Immunology, 2018, 197, 96-106.	1.4	38
26	Complement components, regulators and receptors are produced by human monocyte-derived dendritic cells. Immunobiology, 2007, 212, 151-157.	0.8	35
27	Protective Effects of the Complement Inhibitor Compstatin CP40 in Hemorrhagic Shock. Shock, 2019, 51, 78-87.	1.0	34
28	Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. Nature Cancer, 2021, 2, 218-232.	5.7	34
29	Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates. Molecular Therapy - Methods and Clinical Development, 2017, 6, 207-215.	1.8	33
30	Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Seminars in Hematology, 2018, 55, 167-175.	1.8	32
31	Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. Trends in Immunology, 2017, 38, 383-394.	2.9	31
32	C3 complement inhibition prevents antibody-mediated rejection and prolongs renal allograft survival in sensitized non-human primates. Nature Communications, 2021, 12, 5456.	5.8	29
33	Impaired dendritic cell differentiation and maturation in the absence of C3. Molecular Immunology, 2008, 45, 1952-1962.	1.0	26
34	CMAp: Complement Map Database. Bioinformatics, 2013, 29, 1832-1833.	1.8	26
35	Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis. Journal of Proteome Research, 2018, 17, 3153-3175.	1.8	24
36	Rare Loss-of-Function Mutation in Complement Component C3 Provides Insight into Molecular and Pathophysiological Determinants of Complement Activity. Journal of Immunology, 2015, 194, 3305-3316.	0.4	23

#	ARTICLE	IF	CITATIONS
37	Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia. <i>Clinical Immunology</i> , 2016, 171, 32-35.	1.4	23
38	New Analogs of the Complement C3 Inhibitor Compstatin with Increased Solubility and Improved Pharmacokinetic Profile. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6153-6162.	2.9	23
39	Systems Analysis of the Complement-Induced Priming Phase of Liver Regeneration. <i>Journal of Immunology</i> , 2016, 197, 2500-2508.	0.4	22
40	Complement C3 inhibition by compstatin Cp40 prevents intra- and extravascular hemolysis of red blood cells. <i>Haematologica</i> , 2020, 105, e57-e60.	1.7	17
41	Prolonged intraocular residence and retinal tissue distribution of a fourth-generation compstatin-based C3 inhibitor in non-human primates. <i>Clinical Immunology</i> , 2020, 214, 108391.	1.4	16
42	Nonsense-codon-mediated decay in human hereditary complement C3 deficiency. <i>Immunogenetics</i> , 2004, 55, 667-673.	1.2	14
43	From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage. <i>Immunobiology</i> , 2016, 221, 1046-1057.	0.8	14
44	Conjugation to Albumin-Targeting Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin. <i>ChemMedChem</i> , 2014, 9, 2223-2226.	1.6	13
45	Taming hemodialysis-induced inflammation: Are complement C3 inhibitors a viable option?. <i>Clinical Immunology</i> , 2019, 198, 102-105.	1.4	11
46	Method development and validation for the quantitation of the complement inhibitor Cp40 in human and cynomolgus monkey plasma by UPLC-ESI-MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1041-1042, 19-26.	1.2	8
47	Complement component C3aR constitutes a novel regulator for chick eye morphogenesis. <i>Developmental Biology</i> , 2017, 428, 88-100.	0.9	8
48	Novel Immunoassay for Complement Activation by PF4/Heparin Complexes. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1484-1487.	1.8	7
49	A sweet spot to control complement-induced inflammation. <i>Nature Medicine</i> , 2012, 18, 1340-1341.	15.2	6
50	Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads. <i>Frontiers in Immunology</i> , 2019, 10, 3029.	2.2	6
51	Complement C5a-Mediated TAM-ing of Antitumor Immunity Drives Squamous Carcinogenesis. <i>Cancer Cell</i> , 2018, 34, 531-533.	7.7	4
52	A regulatory role for the C5a anaphylatoxin in TH17 cell differentiation. <i>Molecular Immunology</i> , 2008, 45, 4108.	1.0	0